2019 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020
Contents:
- Executive Summary - pp. 2-8 (7 pages)
- Laboratory Report -– pp. 9-37 (28 pages)
- Sport Report - pp. 38-174 (137 pages)
- Testing Authority Report - pp. 175-313 (139 pages)
- ABP Report-Blood Analysis - pp. 314-355 (42 pages)
Report Highlights
- A 5.5% increase in the overall number of samples analyzed: 263,519 in 2018 to 278,047 in 2019.
- A slight decrease in the total percentage of Adverse Analytical Findings (AAFs): 1.05% in 2018 (2,774 AAFs from 263,519 samples) to 0.97% in 2019 (2,702 AAFs from 278,047 samples).
- About 60% of WADA-accredited Laboratories saw an increase in the total number of samples recorded.
- An almost similar total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.3% in 2018 (24,495 of 263,519) and 9.1% in 2019 (25,339 of 278,047).
- An increase of 16% in the number of ABP blood samples tested: 31,265 in 2018 to 36,401 in 2019.
- An increase in AAFs reported for Erythropoiesis Stimulating Agents (ESAs), Growth Hormone (GH) and Growth Hormone Releasing Factors (GHRFs).
The World Anti-Doping Agency (WADA) has published its 2019 Testing Figures Report (2019 Report), which summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2019.
This is the fifth set of global testing figures under the version of the World Anti-Doping Code (Code) that came into effect in January 2015. The 2019 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting AAFs and Atypical Findings (ATFs).
